| ID | 1186 |
| Name of the vaccine | CVD 1208S |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Live attenuated |
| Nucleic acid content | DNA |
| Age | 18 to 45 years |
| Description of the vaccine | Shigella flexneri 2a live vaccine. |
| Name of the manufacturer | University of Maryland, Baltimore |
| Name of the manufacturing country | United States |
| Year of manufacture | 2010 |
| Clinical Phase status | Clinical - Terminated |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Liquid |
| Dosage | Three doses, one month apart. |
| Mechanism of action | Anti-lipopolysaccharide responses, interferon gamma production in response to Shigella antigens. |
| Route of administration | Oral |
| Indications | Prevents infection with the Shigella. |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 17938573 |
| Clinical trial number | NCT00866476 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|